The idea to impede the interactions of uPAR with uPA or IGF1R, as demonstrated by us, using the combined knockdown of the target proteins and leading to decreased malignancy in vitro may be thinkable for the future, to inhibit tumour progression in vivo by treating TNBC patients with inhibitors targeting these biomarkers in combination. Here, PLAU is linked to neoplasm.